| Literature DB >> 26688728 |
Andréa Lúcia Gonçalves da Silva1, Maribel Josimara Bresciani2, Thaís Evelyn Karnopp2, Augusto Ferreira Weber2, Joel Henrique Ellwanger3, João Antonio Pêgas Henriques4, Andréia Rosane de Moura Valim5, Lia Gonçalves Possuelo5.
Abstract
BACKGROUND: Tuberculosis (TB), Lung Cancer (LC) and Chronic Obstructive Pulmonary Diseases (COPD) affect millions of individuals worldwide. Monitoring of DNA damage in pathological situations has been investigated because it can add a new dimension to clinical expression and may represent a potential target for therapeutic intervention. The aim of this study was to evaluate DNA damage and the frequency of cellular abnormalities in TB, LC and COPD patients by comparing them to healthy subjects.Entities:
Keywords: Apoptosis; Micronucleus; Necrosis; Pulmonary diseases
Year: 2015 PMID: 26688728 PMCID: PMC4684909 DOI: 10.1186/s40248-015-0034-z
Source DB: PubMed Journal: Multidiscip Respir Med ISSN: 1828-695X
Characteristics of research subjects
| COPD | LC | TB | Control | |
|---|---|---|---|---|
|
|
|
|
| |
| Sex (male) | 14 | 13 | 16 | 9 |
| Ethnicity (Caucasian) | 23 | 14 | 10 | 17 |
| Age (years)a | 64.21 ± 8.20 | 65.06 ± 6.64 | 36.09 ± 16.25 | 62.82 ± 4.78 |
| BMIa | 24.47 ± 4.35 | 24.44 ± 4.13 | 23.67 ± 3.74 | 26.40 ± 3.90 |
| Smoking status Never/Ex/Smoker | 1/24/3 | 0/14/4 | 9/4/9 | 9/8/0 |
| Cigarretes-yearb,c | 7300 (730–25550) | 7300 (1460–21900) | 6387 (5475–14600) | 7200 (1800–10800) |
n sample size, COPD Chronic Obstructive Pulmonary Disease, LC Lung Cancer, TB Tuberculosis, BMI Body Mass Index. aExpressed as mean ± SD; bCigarettes smoked per year for smokers and ex-smokers; c Expressed as median (min.-max.)
Micronuclei frequencies and cellular abnormalities in COPD, TB, LC patients and control subjects
| % | COPD | LC | TB | Control |
|---|---|---|---|---|
|
|
|
|
| |
| Normal cells | 0.15 (0.00–0.30)a,c | 0.15 (0.05–0.35)a | 0.65 (0.40–0.90)d | 0.35 (0.10–3.00) |
| MN (basal cells) | 0.00 (0.00–0.05) | 0.00 (0.00–0.05) | 0.00 (0.00–0.10) | 0.00 (0.00–0.05) |
| MN (differentiated cells) | 0.20 (0.00–0.35)a,c | 0.15 (0.05–0.30)a | 0.50 (0.30–0.70)a,d | 0.30 (0.50–3.00) |
| Nuclear bud | 0.10 (0.00–0.25)a,c | 0.10 (0.05–0.30)a | 0.25 (0.10–0.50)d | 0.20 (0.00–1.20) |
| Binucleated cells | 0.10 (0.05–0.20)a,c | 0.15 (0.05–0.30)a | 0.30 (0.10–0.60)a | 0.65 (0.15–1.55) |
| Condensed chromatin | 0.95 (0.40–2.25)a,c | 0.97 (0.40–1.90)a | 2.20 (0.60–6.60)a,d | 0.05 (0.00–0.60) |
| Karyorrhectic cells | 2.05 (0.75–3.40)a,b | 1.12 (0.35–1.95) | 1.65 (0.80–4.50)a | 0.25 (0.00–5.00) |
| Pyknotic cells | 3.00 (1.50–3.90)a,b,c | 1.37 (0.40–3.15)a | 2.55 (0.80–4.40)a,d | 0.15 (0.00–0.50) |
| Karyolitic cells | 2.10 (0.60–3.10)b | 0.85 (0.40–1.95)a | 2.20 (0.90–3.60)d | 1.85 (0.40–5.20) |
n sample size, COPD Chronic Obstructive Pulmonary Disease, LC Lung Cancer, TB Tuberculosis, MN Micronucleus. Expressed as median (50 %) and quartiles (25 % – 75 %); a p ≤ 0.05 between cases (COPD or LC or TB) and controls; b p ≤ 0.05 between COPD and LC; c p ≤ 0.05 between COPD and TB; d p ≤ 0.05 between TB and LC